Star Combo Pharma Ltd. (S66) AI Stock Analysis

• Market Cap: AU$22.28M
• Dividend Yield: 2.24%
• Average Volume (3M): 1.66K
• Price to Earnings (P/E): 25.0
• Beta (1Y): -0.05
• Revenue Growth: 16.45%
• EPS Growth: 83.33%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 41
• Industry: Household & Personal Products
• EPS (TTM): <0.01
• Shares Outstanding: 135,002,980
• 10 Day Avg. Volume: 2,513
• 30 Day Avg. Volume: 1,663
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 62 Neutral
• Price Target: AU$0.00 ▼(-100.00%Downside)

Star Combo Pharma Ltd. scores moderately due to its stable financial position and positive technical indicators. However, the stock's overvaluation and overbought technical conditions suggest potential risks. The company needs to improve its profitability and cash flow management to enhance its financial health.

Star Combo Pharma Ltd. Business Overview & Revenue Model

Company Description

Star Combo Pharma Limited engages in the manufacturing and distribution of health food products and nutritional supplements in Australia and China. The company operates in two segments, Star Combo and Austoyou Retail. It develops, manufactures, markets, and sells natural health supplements and skin care products. The company provides its products through e-commerce platform to Chinese health product consumers; and two retail stores in Sydney. Star Combo Pharma Limited was founded in 2004 and is based in Smithfield, Australia.

How the Company Makes Money

Star Combo Pharma Ltd. generates revenue primarily through the sale of its health and wellness products. The company's key revenue streams include direct sales to consumers, distribution agreements with retailers, and export sales to international markets. The company leverages its manufacturing capabilities to produce high-quality products, which are then marketed under its own brand as well as through private label arrangements. Strategic partnerships with distributors and retailers enhance its market reach, while continuous investment in product development helps maintain a competitive edge. These factors collectively contribute to the company's earnings.

Star Combo Pharma Ltd. Financial Statement Overview

Summary

Star Combo Pharma Ltd. demonstrates moderate financial health with stable revenue growth and low leverage. However, profitability and cash flow conversion remain areas of concern, suggesting potential operational inefficiencies. The company should focus on enhancing its cash flow management and improving profitability to strengthen its financial position.

Income Statement

Star Combo Pharma Ltd. shows a moderate financial performance with a Gross Profit Margin of 20.9% and a Net Profit Margin of 2.9%. The Revenue Growth Rate is 5.3% annually, indicating a steady increase in sales. However, the EBIT Margin is 2.8%, showcasing limited operational efficiency. While EBITDA Margin stands at 10.7%, there is room for improvement in profitability metrics.

Balance Sheet

The balance sheet reflects a stable financial position, with a Debt-to-Equity Ratio of 0.12, indicating low leverage and financial risk. Return on Equity is 2.2%, showing room for improvement in profitability. The Equity Ratio is high at 77.9%, suggesting a strong reliance on equity financing, which enhances stability.

Cash Flow

The cash flow statement reveals some challenges, with a negative Free Cash Flow Growth Rate of 106.4%, indicating deteriorating cash generation. The Operating Cash Flow to Net Income Ratio is negative, as is the Free Cash Flow to Net Income Ratio, signaling inefficiencies in converting income to cash.

Breakdown
Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
26.02M	24.70M	22.88M	26.72M	38.84M
	Gross Profit
5.44M	7.16M	5.61M	4.61M	5.29M
	EBIT
723.43K	1.14M	549.23K	-889.82K	-512.54K
	EBITDA
2.79M	-2.53M	-126.71K	-6.40M	352.23K
	Net Income Common Stockholders
747.33K	-4.00M	-696.35K	-7.88M	-348.69K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
7.36M	9.49M	10.39M	17.32M	26.60M
	Total Assets
42.82M	42.23M	43.44M	43.32M	54.72M
	Total Debt
4.03M	4.19M	4.12M	3.30M	5.61M
	Net Debt
1.86M	-5.30M	-6.27M	-14.03M	-20.99M
	Total Liabilities
9.30M	8.97M	8.04M	7.13M	10.22M
	Stockholders Equity
33.32M	33.09M	35.41M	36.19M	44.50M
Cash Flow		Free Cash Flow
-1.76M	-851.83K	-7.21M	-6.93M	-3.80M
	Operating Cash Flow
-316.45K	1.88M	87.11K	331.53K	-1.02M
	Investing Cash Flow
-136.79K	-3.23M	-3.24M	-7.53M	-3.63M
	Financing Cash Flow
-370.93K	-53.44K	-169.08K	-2.08M	26.63M

Star Combo Pharma Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.16
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:S66, the sentiment is Negative. The current price of 0.16 is above the 20-day moving average (MA) of 0.16, above the 50-day MA of 0.14, and above the 200-day MA of 0.14, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 32.85 is Neutral, neither overbought nor oversold. The STOCH value of 78.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:S66.

Star Combo Pharma Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
S66	62 Neutral	AU$22.28M	25.00	2.68%	2.24%	16.45%	83.33%
Sector *	54 Neutral	$5.31B	3.26	-45.10%	2.79%	16.76%	0.02%
CMXHF		$76.28B	26.67	15.38%	1.85%	―	―
CYYNF		$25.01M	―	-75.39%	―	―	―
SDI	76 Outperform	AU$101.04M	9.57	11.40%	4.00%	0.82%	31.36%
CMX	34 Underperform		―	-80.70%	―	―	1.55%

Star Combo Pharma Ltd. Corporate Events

Star Combo Pharma Secures $5 Million Insurance Settlement Post-Factory Fires

Star Combo Pharma Ltd announced the settlement of insurance claims related to damages from two fires at its factory in 2022, resulting in a $5 million payment. This settlement is expected to provide financial relief and stability, potentially enhancing the company’s operational capabilities and market positioning.

Star Combo Pharma Announces Registry Office Relocation

Star Combo Pharma Ltd has announced a change in the address of its registry office, MUFG Corporate Markets (AU) Limited, which will now be located at Liberty Place, Level 41, 161 Castlereagh St, Sydney NSW 2000. This move, effective from 14 April 2025, does not affect the company’s telephone numbers or postal address. The announcement reflects the company’s ongoing operational adjustments and is approved by the Company Secretary, Patrick Raper.